Inhibitory mechanism of ternary fusion protein MSIK on HPV virus.

OBJECTIVE: We investigated whether the ternary fusion protein (MBP-SERPINA3-IFN-κ, MSIK) can inhibit the proliferation of human papillomavirus (HPV) and the possible mechanism of this inhibitory effect. MATERIALS AND METHODS: First, the purchased MSIK protein was prepared into MSIK protein solutions of different concentrations, and then epithelial cells and 300 mice were involved in the research. The HSV-1 virus was used as the infection pathogen to explore the mechanism of MSIK reinhibition of HPV virus. The virus content in each sample was detected by PCR technology. RESULTS: Epithelial cells treated with different concentrations of MSIK had inhibitory effects on the invasion and replication of HSV-1 virus. MSIK protein had a positive effect on wound healing in mice at the same time, and it had an inhibitory effect on the invasion of HSV-1 virus, and the higher concentration of MSIK, the better the effect. CONCLUSIONS: MSIK can quickly help wound healing and inhibit the replication of HSV-1 virus. It can also effectively prevent the influx of HPV virus and replication has a positive effect on the prevention and treatment of HPV virus.

Pharmacy management of a patient with coronary heart disease and mental disorders.

BACKGROUND: The aim of our study was to find the entry point of pharmaceutical management according to the own situation of a patient with coronary heart disease and psychological disorders. CASE REPORT: Clinical pharmacists adjusted and optimized the drug treatment plan according to the patient's own individual situation from the perspective of the psychological disorder after coronary heart disease operation. The plan proposed by clinical pharmacists was adopted by clinicians, and the patient's rehabilitation treatment effect was obvious. CONCLUSIONS: Clinical pharmacists can actively play a role in the treatment process, providing individualized drug treatment adjustments and optimization plans for clinicians, therefore improving the therapeutic effect.

A real-world study of Chinese hepatocellular carcinoma patients treated with TACE.

OBJECTIVE: The aim of the study was to explore the real situation of transcatheter arterial chemoembolization (TACE) treatment mode and clinical benefits for hepatocellular carcinoma (HCC) patients, as well as to potentially provide data support and clinical basis for the decision-making of HCC patients. PATIENTS AND METHODS: We collect the diagnosis and treatment information of patients who were clinically diagnosed with primary liver cancer (PLC) and received the first treatment in the medical center since January 1st, 2012 from the Chinese Liver Cancer Survey (CLCS) database. Then, we entered the formatted data into the real-world study (RWS) database. TACE-related data were collected prospectively. From December 2018 to January 2020, HCC patients who were eligible for CLCS and received TACE were treated at three time points (admission day/before TACE, before discharge/after TACE, follow-up/first follow-up after discharge) to collect and analyze the quality of life of patients and the use of medical resources. Patients with clinical diagnosis of HCC who received TACE treatment at least once were screened based on CLCS locking data. Demographic and TACE treatment related studies were conducted on the selected HCC patients. RESULTS: The data of the whole group of 5436 HCC patients who received TACE treatment in 48 medical centers showed that the first department of patients was surgery (65.89%), followed by internal medicine (22.42%) (p>0.05). The proportion of patients treated with TACE was 51.85%; the proportion of patients treated with 2 TACE was 23.64%; the proportion of patients with more than 3 times was 20.60% (p>0.05). In the CLCS database, the TACE-first group, there were 1758 patients who received only one treatment in total, and 3069 patients who received ≥ 2 treatments (p<0.05). The common complications related to TACE treatment were nausea (25.77%), fever (31.53%), vomiting (20.99%), liver pain (40.67%) and other uncomfortable symptoms (p<0.05). CONCLUSIONS: A more comprehensive understanding of the clinical impact and benefits of TACE in Chinese HCC patients is needed.